Carotuximab, also known as TRC105 while DE-122, represents a unique antibody-drug conjugate therapeutic currently evaluated for managing various oncological conditions. This specific molecule selects a defined antigen, present on tumor cells, administering a powerful cytotoxic agent directly to the affected area. Initial clinical trials have shown

The emergence of amivantamab offers a exciting development for patients battling cancers exhibiting c-MET overexpression. This unique therapeutic, a targeted blocker of both MET kinase plus human epidermal growth factor receptor 2 (HER2), revealed preliminary effectiveness in patient assessments, particularly in patients whose tumors harbor exhibit